Right vs. left cardiac function and structure: impact of SGLT2i in acute decompensate heart failure with central sleep apnea

29 August 2025 (07:00 - 18:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Assistant Professor Petar Kalaydzhiev

University Hospital Tsaritsa Yoanna, Sofia (Bulgaria)

3 More presentations in this session

Presentation thumbnail

Two years follow-up of use of SGLT2 inhibitors in HFrEF patients hospitalized for decompensation

Associate Professor V. Vintila (Bucharest, RO)

Abstract Slides Video

Presentation thumbnail

SGLT2 inhibitors improve cardiovascular clinical outcomes in patients undergoing anthracycline chemotherapy: a systematic review and meta-analysis of 13,333 patients.

Doctor L. Spadafora (Latina, IT)

Abstract Slides Video

Presentation thumbnail

THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure.

Doctor S. Das (Boston, US)

Access the full session

Session thumbnail

SGLT2 inhibitors in heart failure: prevention and treatment

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025

You may be interested in

Congress Presentation

Effect of sglt2-inhibitors on polygraphic parameters in elderly patients affected by heart failure and sleep apnea

Congress Presentation

Cardiometabolic benefits of dual GLP1-RA and SGLT2i therapy in patients with HFpEF, T2DM, obesity, and obstructive sleep apnea: a prospective study

Congress Presentation

Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction - Results from the REWIN-HFrEF Study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources